Gene therapy using the human telomerase catalytic subunit gene promoter enables targeting of the therapeutic effects of vesicular stomatitis virus matrix protein against human lung adenocarcinoma

PING ZHANG1*, JIAO TAN1*, DA-BING YANG1, ZI-CHAO LUO2, SHAN LUO1, PING CHEN1, PING SUN1, YI ZHOU1, XIAN-CHENG CHEN1, YU-QUAN WEI1 and YAN-JUN WEN1

1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041; 2CAS/CUHK Research Centre for Biosensors and Medical Instruments, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518005, P.R. China

Received April 20, 2012; Accepted July 26, 2012

DOI: 10.3892/etm.2012.679

Correspondence to: Professor Yan-Jun Wen, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, 1 Keyuan Road 4, Gaopeng Street, High Technological Development Zone, Chengdu, Sichuan 610041, P.R. China
E-mail: julio_wy@sohu.com

*Contributed equally

Key words: vesicular stomatitis virus matrix protein, phTERT-M, pVAX-M, apoptosis, targeted antitumor effect

Abstract. The catalytic subunit of telomerase, human telomerase reverse transcriptase (hTERT), is highly active in immortalized cells and more than 90% of human cancer cells, but is quiescent in the majority of normal somatic cells. Thus, the hTERT promoter has been extensively used in targeted cancer gene therapy. Vesicular stomatitis virus (VSV) matrix protein (MP) induces the apoptosis of tumor cells in the absence of other viral components. In our previous studies, we successfully constructed the pVAX-M plasmid from the pVAX plasmid, which expressed wild-type VSV MP (VSV MP is under the control of the CMV promoter) and demonstrated that pVAX-M efficiently suppresses the growth of malignant tumors via the induction of apoptosis in vitro and in vivo. The present study was designed to construct the plasmid phTERT-M (VSV MP is under the control of the hTERT promoter) and investigate whether it had a targeted antitumor effect in nude mice bearing human lung adenocarcinoma. In vitro, A549 human lung adenocarcinoma cells were treated with NS, Lip-null, etoposide, Lip-pVAX-M or Lip-phTERT-M, and examined for cell viability through MTT assays or for apoptosis by flow cytometry and TUNEL assays. In vivo, A549 human lung carcinoma models in nude mice were established. Mice were treated with 10 4-weekly intravenous administrations of NS, Lip-null, etoposide (2 mg/kg), Lip-pVAX-M or Lip-phTERT-M. Subsequently, Lip-phTERT-M was found to be the most efficient inhibitor of tumor growth and inducer of tumor cell apoptosis when compared with the other groups in vivo and in vitro (P<0.05). Notably, immunohistochemical staining showed that Lip-phTERT-M significantly limited the overexpression of VSV MP to the tumor tissues and reduced VSV MP expression in other organs in comparison with Lip-pVAX-M (P<0.05). Therefore, it can be concluded that phTERT-M demonstrates a targeted antitumor effect on A549 human lung adenocarcinoma cells. These observations suggest that phTERT-M gene therapy may be a novel and potent strategy for targeting human lung adenocarcinoma.

Introduction

Human telomerase is a specialized DNA polymerase which controls the replication of chromosomal ends, or telomeres. The majority of malignant tumors express telomerase but most normal cells do not (1,2). Therefore, telomerase may be a good candidate for targeted cancer gene therapy. Human telomerase consists of 3 major components: the RNA component (hTER); the telomerase-associated protein (hTEP1); and the telomerase catalytic unit or human telomerase reverse transcriptase (hTERT) (3-5). Both hTER and hTERT are necessary for telomerase activity, although telomerase expression is predominantly regulated at the transcriptional level of hTERT. Additionally, hTER expression is specific to human tumor cells, whereas hTERT is present in normal and tumor cells. Thus, the hTERT promoter has been extensively used in targeted cancer gene therapy (6-13).

Vesicular stomatitis virus (VSV) is a negative-stranded RNA rhabdovirus with a single molecule genome. VSV includes 5 major proteins [nucleoprotein (N); phosphoprotein (P); matrixprotein (M); glycoprotein (G) and polymerase (L)] and selectively replicates in interferon (IFN)-resistant tumor cells. VSV also induces host cell apoptosis via signaling
through the double-stranded RNA-dependent serine/threonine protein kinases, Fas and Daxx (14-16). Studies have confirmed that VSV efficiently suppresses the growth of syngeneic tumors in immunocompetent mice and human tumor xenografts in nude mice and prolongs the survival time of tumor-bearing animals. However, severe adverse effects, including flu-like symptoms, encephalitis, ventriculitis, oral vesicles and cervical lymphadenopathy, limit the clinical applications of replication-competent VSV (17-20). Matrix protein (MP) is important in viral assembly and cytopathogenesis. Expression of MP alone causes a number of the same cellular effects as infection with VSV via the inhibition of host gene transcription and nucleocytoplasmic transport of host RNAs and proteins (21-24). Previously, we constructed the plasmid pVAX-M (VSV MP is under the control of the CMV promoter) and revealed that pVAX-M alone or combined with radiation or DDP efficiently inhibits solid tumor growth and significantly prolongs survival (25-29). These findings suggest that VSV MP is a promising agent for the treatment of tumors.

In the present study, in order to realize the targeted antitumor effect of VSV MP, the plasmid phTERT-M (VSV MP controlled by the hTERT promoter) was constructed. Subsequently, we found that phTERT-M suppressed the tumor growth of the A549 model, limited VSV MP overexpression to the tumor tissues and reduced VSV MP expression in other organs more effectively than pVAX-M. These results demonstrate that phTERT-M gene therapy is a more specific and safer approach for the treatment of human lung adenocarcinoma than pVAX-M gene therapy.

Materials and methods

Cell line. The human lung adenocarcinoma A549 cell line was obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). It was cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml of penicillin, 100 mg/ml of streptomycin and maintained in a 37°C incubator with a humidified 5% CO₂ atmosphere.

Plasmid construction, preparation of cationic liposome and liposome-DNA complex. pVAX-M from the pVAX plasmid (Invitrogen Life Technologies, San Diego, CA, USA) expressing wild-type VSV MP, was constructed in our laboratory previously (25-29). As a control, pure pVAX plasmid without VSV MP-cDNA was used as an empty vector (null). A 271-bp fragment containing the core promoter region of tumors. Subsequently, we found that phTERT-M suppressed the tumor effect of VSV MP, the plasmid phTERT-M (VSV MP controlled by the hTERT promoter) was constructed.

Cell viability assay in vitro. The cytotoxicity of phTERT-M-liposome mixtures or pVAX-M-liposome mixtures on A549 cells was determined using the 3-(4,5-dimethylthiazolol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma, St. Louis, MO, USA) colorimetric assay. Cells (~5,000 cells/100 µl medium) were seeded in each well of a 96-well plate and incubated overnight. The cells were then treated with NS, Lip-null (0.2 µg pVAX/0.6 µg liposome mixtures), Lip-phTERT-M (0.2 µg phTERT-M/0.6 µg liposome mixtures), Lip-pVAX-M (0.2 µg pVAX-M/0.6 µg liposome mixtures) and etoposide (0.1 µg/ml), respectively. Six wells were included in each group. After a 48-h incubation, the medium was aspirated and 20 µl of 5 mg/ml MTT was added per well and incubated at 37°C for 4 h; then supernatant fluid was removed and 150 µl dimethyl sulfoxide (DMSO) was added per well. Spectrometric absorbance at 540 nm was measured using a microplate reader. The cell survival rate was assessed as percent cell viability in terms of non-treated control cells.

Assessment of apoptosis in vitro. Cell apoptosis was evaluated by flow cytometry and TUNEL assay (DeadEnd Fluorometric TUNEL System; Promega Corporation, Madison, WI, USA). Flow cytometric analysis was performed as previously reported (26,27). Cells (~2x10⁵ cells/well) were plated in 6-well plates and treated with NS, Lip-null (2 µg pVAX/6 µg liposome mixtures), Lip-phTERT-M (2 µg phTERT-M/6 µg liposome mixtures), Lip-pVAX-M (2 µg pVAX-M/6 µg liposome mixtures) or etoposide (0.1 µg/ml). After a 48-h incubation, the cells were collected and resuspended in 1 ml hypotonic fluorochrome solution containing 50 µg/ml propidium iodide (PI) in 0.1% sodium citrate with 0.1% Triton X-100 and then analyzed by flow cytometry. Cells appearing in the sub-G1 stage were considered as apoptotic cells. To quantify apoptotic cells within the total tumor cells in vitro, TUNEL assays were performed according to the manufacturer’s instructions. Cell nuclei with dark green fluorescent staining were defined as TUNEL-positive nuclei. TUNEL-positive nuclei were monitored by fluorescence microscope (Leica, Bensheim, Germany). Five equal-sized fields at x200 magnification were randomly chosen and analyzed. The apoptotic index (AI) was defined as follows: AI (%) = 100 x (apoptotic cells/total tumor cells).

Animal studies. Female athymic BALB/c nude mice (SPF grade; 6- to 8-weeks old), were purchased from the Laboratory Animal Center of Sichuan University and allowed to acclimate for 1 week before use. All the animal studies were carried out in accordance with institutional guidelines referring to animal use and care. A549 cells (~5x10⁵) were injected into the right flank of each nude mouse via subcutaneous inoculation. When the size of the tumors reached ~30 mm³, mice were randomly assigned into 5 groups and treated with NS (100 µl), Lip-null (10 µg pVAX/30 µg liposome mixtures, 100 µl), Lip-phTERT-M (10 µg pVAX-M/30 µg liposome mixtures, 100 µl), Lip-pVAX-M (10 µg pVAX-M/30 µg liposome mixtures, 100 µl) or etoposide (2 mg/kg). The animals received 10 4-weekly intravenous administrations and were monitored every 3 days for tumor burden, cachexia and other abnormalities. Tumor sizes were measured using the formula A x B² x 0.52 (A, length; B, width;
all in mm). All data are presented as mean ± SD. Mice were sacrificed by cervical dislocation when the volume of the tumor exceeded 6,000 mm$^3$. Tissues of interest, including heart, liver, spleen, lung, kidney and tumor, were excised and fixed in 10% neutral-buffered formalin solution or frozen at -80°C.

**Histological analysis.** To analyze the targeted antitumor effect of phTERT-M against the A549 model, immunohistochemical staining was performed as described previously (26). The tissues of each group were embedded in paraffin and cut into 3- to 5-µm sections. These sections were then deparaffinized in xylol and rehydrated through a graded alcohol series. Antigen retrieval was performed by autoclaving sections in 10 mM EDTA (pH 6.0) and incubating them with rabbit immunoserum at 1:50 dilution, followed by an incubation with biotinylated rat anti-rabbit antibody and then streptavidin biotin reagents.

To quantify apoptotic cells within the tumor sections, TUNEL assays (DeadEnd Fluorometric TUNEL System; Promega Corporation) were performed according to the manufacturer's instructions. Five equal-sized fields at x200 magnification were randomly chosen and analyzed. The apoptotic index (AI) was defined as explained above.

**Toxicity observation.** No significant differences in weight were found among the 5 groups. No adverse consequences in other gross measures, including ruffling of fur, behavior, feeding and toxic death, were observed in the Lip-phTERT-M group. Furthermore, no significant differences in liver, lung, kidney, spleen, heart, pancreas or brain were observed by hematoxylin and eosin histological examination between the Lip-phTERT-M and NS groups.

**Statistical analysis.** All the data were analyzed by the statistical software SPSS 16.0. Data were assessed by ANOVA and Student’s t-test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**The antitumor efficacy of Lip-phTERT-M on A549 cells in vitro.** In order to evaluate the antitumor activity of Lip-phTERT-M on A549 cells in vitro, cell viability assays using MTT were performed. The results demonstrated that Lip-phTERT-M reduced A549 cell growth more effectively than the other groups (Fig. 1). The apoptotic effect of the 5 groups on A549 cells was quantitated via flow cytometry and TUNEL assays. From the results of flow cytometry, we revealed that the apoptotic cells accounted for 64.5% of the cells in the Lip-phTERT-M group versus 47.8% in the Lip-pVAX-M group, 26.6% in the Lip-null group and 14.7% in the NS group. Furthermore, the results of the TUNEL assays suggested that the AI had been increased the most by Lip-phTERT-M compared with the other groups. Data are represented as the mean AI ± SD of cancer cells, as percentage normalized to the AI of the cancer cells (Fig. 2).

Lip-phTERT-M significantly suppresses tumor growth in the A549 tumor model. The mouse tumor model assay showed that Lip-phTERT-M was more effective in the suppression of tumor growth than the other groups (P<0.05). Additionally, Lip-phTERT-M resulted in >67% inhibition of tumor growth compared with the NS group (P<0.05, 2 days after the completion of treatment). No significant difference in tumor volume was observed among the other groups (Fig. 3).

Lip-phTERT-M increases intratumoral apoptosis in the A549 tumor model. The presence of apoptotic cells within the tumor sections was determined by TUNEL assays. The findings demonstrated that Lip-pVAX-M and Lip-phTERT-M enhanced the apoptotic rate of tumor cells, and a more apparent increase in the number of apoptotic cells was observed within the tumors of the Lip-phTERT-M group. Data are represented as the mean AI ± SD of cancer cells, as a percentage normalized to the AI of the cancer cells (Fig. 4A).

Lip-phTERT-M exhibits a targeted antitumor effect on the A549 tumor model. To investigate the targeted antitumor effect of Lip-phTERT-M, immunohistochemical staining was carried out. The results demonstrated that Lip-phTERT-M resulted in an apparent increase in VSV MP expression in the tumor and the kidney cells, whereas expression in the liver, the spleen and the lung was significantly reduced in comparison with Lip-pVAX-M (P<0.05). Moreover, VSV MP expression in

---

**Figure 1. Cell viability assay in vitro by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT).** The MTT assay was performed to observe the viability of cells as described in Materials and methods. The proportion of surviving cells was calculated as a percentage of the control. Data are represented as the mean ± SD of 3 independent experiments. The results showed that both Lip-phTERT-M and Lip-pVAX-M suppressed the growth of A549 cells in vitro. However, Lip-phTERT-M had a superior inhibitory effect. (P<0.05, compared with the other groups.)
the heart in the two groups was low and there was no significant difference between them. These findings demonstrate that Lip-phTERT-M restricted abundant VSV MP expression to the tumor tissues and may have a superior specific antitumor effect to Lip-pVAX-M (Fig. 4B).

Discussion

In order to enhance the efficacy and safety of cancer gene therapy, numerous scientific teams focus on restricting the therapeutic gene expression to tumors. If the therapeutic gene is expressed in all cells, it will affect tumor and normal cells. A tumor-specific promoter system is likely to be useful for solving this problem. However, true tumor-specific promoters are rare and often useful only in particular types of cancer (31,32). hTERT is the catalytic subunit of telomerase, which is highly active in immortalized cells and >90% of human cancers but is inactive in most normal somatic cells. It is apparently a strong and tumor-selective promoter with potential applications in targeted cancer gene therapy (31-33).

VSV MP induces the apoptosis of tumor cells in the absence of other viral components without severe side-effects, unlike VSV (21-24). Our previous studies demonstrated that the plasmid pVAX-M alone or combined with radiation or DDP efficiently inhibited the growth of solid tumors and significantly prolonged survival times (25-29). Thus, VSV MP gene therapy is a promising approach for the treatment of tumors.
In the present study, the plasmid phTERT-M was constructed to investigate whether it was able to inhibit tumor growth selectively and specifically. We discovered that Lip-phTERT-M suppressed A549 cells or the tumor model growth more effectively by inducing a higher rate of apoptosis in A549 cells than Lip-pVAX-M in vitro and in vivo. These findings suggest that Lip-phTERT-M had an enhanced antitumor efficacy against A549 human lung adenocarcinoma cells compared with Lip-pVAX-M in vitro and in vivo. These findings suggest that Lip-phTERT-M had an enhanced antitumor efficacy against A549 human lung adenocarcinoma cells compared with Lip-pVAX-M. Secondly, Lip-phTERT-M resulted in an apparent increase in VSV MP expression in the tumor and kidney, whereas its expression in the liver, the spleen and the lung were significantly reduced in comparison with Lip-pVAX-M (P<0.05). These findings may further demonstrate that Lip-phTERT-M limited the overexpression of VSV MP to the tumor tissues and had a stronger targeted antitumor effect on A549 models in comparison with Lip-pVAX-M. Additionally, Lip-pVAX-M causes more abundant VSV MP expression in the tumors than in the organs, thereby improving its antitumor efficacy and safety. Thus, it may be proposed that the enhanced antitumor efficacy of Lip-phTERT-M is strongly correlated with its targeted antitumor effect.

Our data demonstrated that phTERT-M gene therapy had an apparent targeted antitumor effect against A549 human lung carcinoma models. Given the strong antitumor effect and minimal toxicity, the results of our study may be of significance to the further exploration of the potential applications of this approach in the treatment of human lung adenocarcinoma.
Acknowledgements

This study was supported by the National Natural Science Foundation of China (30973452), the National Key Basic Research Program of China (973 project 2010CB529900) and the Hi-tech Research and Development Program of China (863 project 2007AA021106).

References

1. Poole JC, Andrews LG and Tollefsbol TO: Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene 269: 1-12, 2001.
2. Nakamura TM, Morin GB, Chapman KB, et al: Telomerase catalytic subunit homologs from fission yeast and human. Science 277: 955-959, 1997.
3. Greenberg RA, O'Hagan RC, Deng H, Xiao Q, Hann SR, Adams RR, Lichtsteiner S, Chin L, Morin GB and DePinho RA: Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 18: 1219-1226, 1999.
4. Kanata T, Kyo S, Hamada K, Takakura M, Kitagawa Y, Harada H and Inoue M: Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin Cancer Res 6: 1239-1247, 2000.
5. Abdul-Ghani R, Ohana P, Matouk I, Ayesh S, Ayesh B, Laster M, Bibi O, Giladi H, Molnar-Kimber K, Sughayer MA, et al: Use of transcriptional regulatory sequences of telomerase (hTERT and hTERT) for selective killing of cancer cells. Mol Ther 2: 539-544, 2000.
6. Koga S, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M, Kyo S and Kondo S: A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther 11: 1397-1406, 2000.
7. Koga S, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M, Kyo S and Kondo S: FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo. Anticancer Res 21: 1937-1943, 2001.
8. Komata T, Koga S, Hirohata S, Takakura M, Germano IM, Inoue M, Kyo S, Kondo S and Kondo Y: A novel treatment of human malignant gliomas in vitro and in vivo: FADD gene transfer under the control of the human telomerase reverse transcriptase gene promoter. Int J Oncol 19: 1015-1020, 2001.
9. Komata T, Kondo Y, Kanzawa T, Hirohata S, Koga S, Sumiyoshi H, Srivastava SM, Barna BP, Germano IM, Takakura M, et al: Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res 61: 5796-5802, 2001.
10. Komata T, Kondo Y, Kanzawa T, Ito H, Hirohata S, Koga S, Sumiyoshi H, Takakura M, Inoue M, Barna BP, et al: Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells. Hum Gene Ther 13: 1015-1025, 2002.
11. Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA and Fang B: Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 60: 5359-5364, 2000.
12. Majumdar AS, Hughes DE, Lichtsteiner SP, Wang Z, Lebkowski JS and Vasserot AP: The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther 8: 568-578, 2001.
13. Gu J, Andreeff M, Roth JA and Fang B: hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther 9: 30-37, 2002.
14. Li Q, Wei YQ, Wen YJ, et al: Induction of apoptosis and tumor regression by vesicular stomatitidis virus in the presence of gemcitabine in lung cancer. Int J Cancer 112: 143-149, 2004.
15. Gaddy DF and Lyss B: Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx. J Virol 81: 2792-2804, 2007.
16. Balachandran S and Barber GN: Vesicular stomatitis virus (VSV) therapy of tumors. UOBMB Life 50: 135-138, 2000.
17. Balachandran S, Porosnicu M and Barber GN: Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol 75: 3474-3479, 2001.
18. Stojdl DF, Lichty BD, tenOever BR, et al: VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275, 2003.
19. Ahmed M, Cramer SD and Lyles DS: Sensitivity of prostate tumors to wild-type and M protein mutant vesicular stomatitis viruses. Virology 330: 34-49, 2004.
20. Kopecky SA and Lyles DS: The cell-rounding activity of the vesicular stomatitis virus matrix protein is due to the induction of cell death. J Virol 77: 552-5528, 2003.
21. Kopecky SA and Lyles DS: Contrasting effects of matrix protein on apoptosis in HeLa and BHK cells infected with vesicular stomatitis virus are due to inhibition of host gene expression. J Virol 77: 4658-4669, 2003.
22. Gaddy DF and Lyles DS: Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. J Virol 79: 4170-4179, 2005.
23. Ahmed M, McKenzie MO, Puckett S, Hojnicki M, Poliquin L and Lyles DS: Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J Virol 77: 4646-4657, 2003.
24. Zhong Q, Wen YJ, Yang HS, et al: Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice. Ann Oncol 19: 1584-1591, 2008.
25. Zhao JM, Wen YJ, Li Q, et al: A promising cancer gene therapy agent based on the matrix protein of vesicular stomatitis virus. FASEB J 22: 4272-4280, 2008.
26. Du XB, Lang JY, Xu JR, et al: Vesicular stomatitis virus matrix protein gene enhances the antitumor effects of radiation via induction of apoptosis. Oncol Rep 13: 1205-1214, 2000.
27. Shi W, Tang Q, Chen X, et al: Antitumor and antimetastatic activities of vesicular stomatitis virus matrix protein in a murine model of breast cancer. J Mol Med 87: 493-506, 2009.
28. Luo S, Chen P, Luo ZC, Zhang P, et al: Combination of vesicular stomatitis virus matrix protein gene therapy with low-dose cisplatin improves therapeutic efficacy against murine melanoma. Cancer Sci 101: 1219-1225, 2010.
29. Horikawa I, Cable PL, Alshfari C and Barrett JC: Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 59: 826-830, 1999.
30. Painter RG, Lanson NA Jr, Jin Z, et al: Expression of a suicide gene by the telomere reverse transcriptase promoter for potential post-therapeutic deletion of tumorigenesis. Cancer Sci 96: 607-613, 2005.
31. Shieh GS, Shiu AL, Yo YT, et al: Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model. Cancer Res 66: 9957-9966, 2006.
32. Wirth T, Zender L, Schulte B, Mundt B, et al: A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 63: 3181-3188, 2003.